| Jul 16 |
Kyverna wins RMAT designation for stiff-person syndrome for cell therapy candidate
|
| Jul 16 |
Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
|
| Jul 16 |
Bank Of America, Morgan Stanley And Other 3 Stocks To Watch Heading Into Tuesday
|
| Jul 15 |
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
|
| Jul 3 |
H.C. Wainwright starts Kyverna at neutral, says awaiting more data
|
| Jun 20 |
Kyverna gains as FDA clears trial for lead therapy
|
| Jun 20 |
Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial
|
| Jun 17 |
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)
|
| Jun 14 |
Kyverna stock plunges 28% amid data update on lead drug
|
| Jun 14 |
Dow Tumbles Over 200 Points; Adobe Earnings Top Views
|
